Investor Relations
Skip to content
ViruCure
  • Home
  • About
    • Our Story
    • Team
  • Products
    • Our Products
    • Product Pipeline
  • NADAV Technology
  • Clinical
    • Phase 1/2
    • Preclinical
    • Publications
  • News
  • Contact
ViruCure
  • Home
  • About
    • Our Story
    • Team
  • Products
    • Our Products
    • Product Pipeline
  • NADAV Technology
  • Clinical
    • Phase 1/2
    • Preclinical
    • Publications
  • News
  • Contact

ViruCure to attend the Biotechnology Innovation Organization, 4-7 June, Boston, USA

May 31, 2018August 2, 2018

Come and meet with our CEO & Co-founder, Yoram Drucker at BIO 2018 to learn more about ViruCure’s breakthrough NADAV technology to fight cancer.

Learn More
Categories news
Post navigation
ViruCure to attend the Armed Oncolytic Immunotherapies Summit Europe 2018, 26-28 June, Frankfurt, Germany

Contact Us

info@virucure.com

Linkedin

ViruCure Therapeutics

ViruCure Therapeutics is a biotech company that is developing an oncolytic-virus-based technology platform, NADAV, for the targeted treatment of a wide range of cancers.

© 2018 • ViruCure